Background: The optimal antithrombotic strategy for patients with atrial fibrillation (AF) undergoing drug-eluting stent (DES) implantation is unknown.
ual antiplatelet therapy (combined aspirin and clopidogrel) is the cornerstone of the treatment of patients undergoing drug-eluting stent (DES) implantation to reduce the risk of stent thrombosis, 1 although chronic oral anticoagulant therapy with warfarin is recommended as the optimal strategy for high-risk patients with atrial fibrillation (AF) to prevent stroke and thromboembolism. 2, 3 However, in patients with AF undergoing DES implantation, warfarin in addition to dual antiplatelet therapy has been associated with up to 5-fold increases in total bleeding complications, 3-8 but withholding warfarin is reported to increase the risk of stroke or thromboembolism. 9,10 Therefore, the optimal antithrombotic regimen in this setting is still unknown. Furthermore, all the existing studies to date had a high proportion of bare metal stent usage, so scarce data are available for assessing the efficacy of different antithrombotic regimens in the DES era, the implantation of which requires prolonged dual antiplatelet therapy to minimize the risk of late stent thrombosis.
Our aim was to evaluate current practice and long-term outcomes of the different antithrombotic regimens for patients with AF following DES implantation.
Methods
From January 2005 to August 2008, a total of 13,923 consecutive patients underwent coronary intervention with a DES in An Zhen hospital (Beijing, China), which is a teaching hospital performing over 4,000 percutaneous coronary intervention (PCI) procedures each year. Among them, 622 patients had either a history of AF or newly diagnosed AF and were prospectively enrolled. Patients with mechanical valve prosthesis were excluded.
We recorded baseline clinical characteristics and the main risk factors of each patient, including smoking, dyslipidemia,
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hypertension, diabetes, prior myocardial infarction (MI) or revascularization, and previous history of stroke or transient ischemic attack. We also calculated the CHADS2 score of each patient (1 point each for the presence of Congestive heart failure, Hypertension, Age 75 years or older, and Diabetes mellitus and by assigning 2 points for history of Stroke or transient ischemic attack). 11 In patients with previous oral anticoagulation therapy undergoing elective PCI, warfarin was stopped prior to the procedure and until the international normalized ratio (INR) was <1.5. In patients undergoing emergency PCI, warfarin was ceased on the day of procedure. During the procedure, a weight-adjusted bolus of unfractionated heparin (80 IU/kg) was administered to achieve an activated clotting time of 250-300 s. If the target value was not achieved after a bolus of heparin, an additional bolus (2,000-5,000 IU) was given. After the PCI procedure, low-molecular-weight heparin and warfarin were coadministered for 3 days to patients who were considered for chronic oral anticoagulation after discharge. According to their antithrombotic regimen at discharge, patients were divided into the TT group (triple antithrombotic therapy), DT group (dual antiplatelet therapy) and WS group (warfarin and single antiplatelet agent). Individual patient management decisions, such as the antithrombotic regimen, strategy for PCI and other concomitant medications at discharge were exclusively decided by the interventional cardiologist and/or the responsible physicians.
In patients taking warfarin, the target INR was set between 1.8 and 2.5 and was closely monitored after discharge. Initially, measurements of INR were performed weekly after discharge and if the INR had achieved the target value after 3 consecutive visits then measurements were taken monthly. In subjects who were discharged with aspirin and clopidogrel, or warfarin and a single antiplatelet agent, their antiplatelet therapy was ordered to continue for at least 12 months.
Clinical follow-up was conducted either by telephone or 
Endpoint Definitions
Primary endpoint was defined as the occurrence of MACCE, including death, MI, target vessel revascularization, stent thrombosis, or stroke at 12 months. A secondary safety endpoint was major or minor bleeding complications during the follow-up period.
MI was defined as either the development of new pathologic Q waves in at least 2 contiguous leads or, in the absence of pathologic Q waves, an elevation in creatine kinase-MB levels to more than twice the upper limit of normal. Target vessel revascularization was defined as a re-intervention driven by any lesion located in the stented vessel. The indication for repeat revascularization was based on anginal symptoms and a significant angiographic stenosis (>50% diameter stenosis). Stent thrombosis was defined as the presence of an acute coronary syndrome with angiographic or autopsy evidence of thrombus or occlusion, and unexplained death within 30 days after the procedure or acute MI involving the target-vessel territory without angiographic confirmation. 12 Bleeding complications were classified according to Thrombolysis In Myocardial Infarction criteria. 13 Major bleeding was defined as any intracranial bleeding or any bleeding associated with clinically overt signs and a drop in hemoglobin >5 g/dl. Minor bleeding was defined as any clinically overt sign of bleeding associated with a decrease in hemoglobin between 3 and 5 g/dl. Stroke was defined as an ischemic cerebral infarction caused by an embolic or thrombotic occlusion of a major intracranial artery.
Statistical Analysis
Categorical data are presented as frequencies (percentages); continuous data are presented as mean value ± SD. The differences between the treatment combinations were tested with ANOVA. The chi-square or Fisher's exact test was used to compare categorical variables. Survival analyses were conducted by Kaplan-Meier analysis and statistical differences between curves were assessed by log-rank test. Age, sex, paroxysmal AF, cardiovascular risk factors (hypertension, diabetes, heart failure, smoking, hyperlipidemia), estimated glomerular filtration rate <60 ml/min (calculated by modified MDRD equation), 14 previous gastrointestinal ulcer, total number and length of stents, as well as all variables with P<0.20 in the univariate analysis were included in a stepwise Cox proportional hazard model analysis. Hazard ratio (HR) and 95% confidence interval (CI) were calculated. All P-values were 2-sided, and P<0.05 was considered statistically significant. Data were analyzed with SPSS 13.0 (Chicago, IL, USA).
Results
Among the 622 patients with AF undergoing PCI with a DES, the baseline and procedural characteristics were not statistically significantly different among each group except for age, the proportion of paroxysmal AF, previous oral anticoagulation, CHADS2 score, and proton-pump inhibitor usage ( Tables 1,2 ). Of note, 91% of the overall cohort had 1 or more risk factors and 45.8% had a CHADS2 score ≥2, which represented a high-risk population for stroke.
Antithrombotic Regimens Used During Follow-up
Not surprisingly, there was wide variability in antithrombotic regimens. In the overall cohort, 142 patients (22.8%; TT group) continued a triple antithrombotic therapy comprising aspirin (100 mg), clopidogrel (75 mg) and warfarin after discharge; 355 (57.1%; DT Group) were prescribed with dual antiplatelet therapy; 125 (20.1%; WS group) were discharged with warfarin and a single antiplatelet agent (109 patients received clopidogrel and 16 patients received aspirin).
Of the 622 patients, complete follow-up was achieved in 591 (95.0%). The duration of dual antiplatelet prescription in the TT group varied, with 31/136 (22.8%) patients ceasing either aspirin or clopidogrel within 6 months, 12 of them because of major or minor bleeding events, while the remainder were mainly because of gastrointestinal discomfort or economic reasons. In total, 64 (47.0%) patients received triple therapy for at least 1 year. In the DT group, 95.5% of the patients continued dual antiplatelet therapy for at least 12 months, while in the WS group, 92.8% of the patients continued warfarin and a single antiplatelet agent for 12 months. Table 1 .
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Events During Follow-up
In terms of overall cardiovascular events (Table 3) , the results from our study indicated that for AF patients after DES implantation, the administration of warfarin was associated with a statistically significant reduction in the overall MACCE rate, which was largely driven by a significantly reduced incidence of ischemic stroke (0.8% vs 3.6%, P=0.029). In the subgroup analysis, the stroke rate was considerably high (7.5%) among patients whose baseline CHADS2 score was ≥2 and who received dual antiplatelet therapy without warfarin. Of note, there was also a borderline significant reduction in all-cause mortality favoring concomitant warfarin (P=0.079). The occurrence of MI, target vessel revascularization or stent thrombosis was similar between patients with and without warfarin. When comparing the 3 different antithrombotic regimens, the overall MACCE rate was significantly lower in the TT group ( Table 4) . Kaplan-Meier analysis showed that the MACCE-free prognosis was significantly better in the TT group as compared with either the DT group or WS group (log-rank test P=0.013) (Figure 1) . Nevertheless, the incidence of death, MI, target vessel revascularization, and stent thrombosis did not statistically differ among the 3 groups ( Table 4 ). In the Cox regression analysis, administration of warfarin (HR 0.49; 95%CI 0.31-0.77; P=0.002) and baseline CHADS2 score ≥2 (HR 2.09; 95%CI 1.27-3.45; P=0.004) were independent predictors of overall MACCE episodes during the 12-month follow-up ( Table 5 ).
The incidence of major bleeding was comparable among the 3 groups (2.9% vs 1.8% vs 2.5%, P=0.725), whereas the minor bleeding rate was significantly higher in the TT group (8.8% vs 3.3% vs 5.0%, P=0.042). Additionally, in the TT group the majority of minor bleeding events occurred when patients were on triple therapy, whereas less bleeding occurred when patients had stopped either aspirin or clopidogrel during follow-up (Figure 2) . Kaplan-Meier analysis indicated the overall bleeding-free prognosis was the worst in the TT group (log-rank test P=0.035) (Figure 1) . In the Cox regression analysis, age (HR 1.13; 95%CI 1.05-1.20; P=0.001), as well as previous gastrointestinal ulcer (HR 3.07; 95%CI 1.54-6.09; P=0.001), were independent predictors of bleeding events during the 12-month follow-up (Table 5) . Surprisingly, in the TT group, 7 of 16 patients with either a major or minor bleeding event had a prior history of gastro- 
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intestinal ulcer. During the 12-month follow-up, a total of 2,023 INR test results were collected for patients taking warfarin, 1,457 (72.0%) of them were within the therapeutic range (1.8-2.5), and 224 (11.1%) were >3. In patients taking warfarin, the occurrence of bleeding events was not well correlated with the traditional INR cut-off value (2-3). In our study, when major bleeding occurred, the majority of INR values were between 2.5 to 3, 3 of 7 INR values were >3 (4.2, 5.9 and 8.1, respectively), but all 7 INR values were >2.5.
The net clinical outcome, which included the occurrence of any MACCE and/or major bleeding complications during follow-up, was significantly lower in the TT group (Table 4) . In addition, Kaplan-Meier analysis demonstrated that the triple antithrombotic regimen was associated with the best net clinical outcome during the 12-month follow-up (log-rank test P=0.030) (Figure 1) . In the Cox regression analysis, administration of warfarin (HR 0.50; 95%CI 0.33-0.78; P= 0.002), baseline CHADS2 score ≥2 (HR 2.00; 95%CI 1.24-3.24; P=0.005) and previous history of gastrointestinal ulcer (HR 2.34; 95%CI 1.48-3.69; P<0.0001) were independent predictors of net clinical outcome during the 12-month follow-up ( Table 5) .
Discussion
To our knowledge, so far this is the largest prospective study to evaluate different antithrombotic regimen s for patients with AF undergoing DES implantation, and it is also the first study conducted in an Asian population. The results from our study suggest that the major bleeding risk of triple antithrombotic therapy is acceptable if the INR is closely monitored. As well, we confirmed the increased risk of stroke in AF patients taking dual antiplatelet therapy without anticoagulation. Importantly, our data illustrate the reduced incidence of MACCE and better net clinical outcome for patients with triple antithrombotic therapy.
Because of scarce evidence till now, there has been no consensus on the optimal strategy regarding the antithrombotic regimen for patients who require chronic anticoagulation after undergoing coronary stenting. The AF guidelines only give a IIb recommendation for either triple therapy or the combination of warfarin and clopidogrel in this setting and the level of evidence is "C". 2 Hence, as expected, our study results showed that there is wide variability in the antithrombotic regimens adopted in current clinical practice. In a review of existing evidence, a meta-analysis of 4 randomized trials (ISAR, FANTASTIC, STARS, and MATTIS) showed that dual antiplatelet therapy is superior to warfarin plus aspirin in reducing total mortality, major bleeding, nonfatal MI and stent thrombosis in patients following coronary stenting. 15 On the other hand, for the sake of stroke prevention, in the ACTIVE-W study oral anticoagulation showed clear superiority over dual antiplatelet therapy for patients with AF, and the study had to be stopped early than expected. 9 Accordingly, the combination of warfarin and dual antiplatelet therapy was widely prescribed in current clinical practice, and there has been a pressing demand for evaluating the safety and efficacy of triple antithrombotic treatment. The first retrospective study of triple therapy (n=66) was from the Mayo Clinic PCI database, which reported a 9.2% bleeding rate. 5 Similarly, Khurram et al also observed an increased risk of major (6.6% vs 0%, P=0.014) as well as minor bleeding (14.9% vs 3.8%, P=0.01) associated with triple therapy after coronary stenting, as compared with dual antiplatelet therapy. 16 Of note, in the first study all bleeding events occurred in patients with suboptimal control of INR and/or preexisting gastrointestinal disease, emphasizing the importance of bleeding risk stratification and close monitoring of the INR. ACTIVE W investigators also demonstrated that patients with INR values within the therapeutic range were those who showed an actual benefit from anticoagulation therapy. 10 This concept was reinforced by a prospective study in which the INR was strictly controlled within the therapeutic range (2.0-2.5); it reported a similar major and minor bleeding rate in patients taking either triple therapy or dual antiplatelet during 18-month follow-up. 17 However, the duration of triple therapy merely lasted for 1 month in over 50% of the patients because they had undergone bare metal stent implantation. In contrast, all patients in our study received a DES and among patients on triple therapy, 77.2% had the triple regimen for more than 6 months, and 47.0% for at least 1 year. During the follow-up period in the present study, the target INR was set as 1.8-2.5 and regularly monitored after discharge. Additionally, the prophylactic use of proton-pump inhibitors was high in our study (56.3%). Therefore, we also demonstrated that the major bleeding rate in patients on prolonged triple therapy was not statistically significantly different when compared with other antithrombotic regimens. However the minor bleeding rate was still higher in patients receiving triple therapy, even though the INR was carefully monitored in them.
Most of the previous studies assessing triple therapy have been either retrospective or small-scale case-control studies focusing on bleeding events, so there is limited information regarding the cardiovascular efficacy of different antithrombotic regimens. In a case-control study, Karjalainen et al 4 compared the occurrence of major adverse cardiac events with different antithrombotic regimens and observed that the incidence of stent thrombosis was lower among patients receiving triple therapy than those receiving warfarin plus aspirin (1.9% vs 15.2%, P=0.004). Meanwhile, stroke was less frequent in patients treated with triple therapy in comparison with the dual antiplatelet regimen (2.8% vs 8.8%), but because of the limited number of patients (n=34) receiving dual antiplatelet therapy, it did not attain statistical significance. In our study, the majority of AF patients were taking dual antiplatelet agents following coronary stenting so there was enough data to highlight the statistically significant increased incidence of stroke in AF patients without concomitant warfarin. In particular, subgroup analysis revealed that among patients whose baseline CHADS2 score was ≥2, the stroke rate was considerably high (7.5%) if they were receiving dual antiplatelet without warfarin. Besides, in the study conducted by Karjalainen et al, subjects had varied clinical indications for oral anticoagulation, and therefore their cardiovascular risks may also have differed, 4 which might pose potential variables between each group. However, our study only enrolled AF patients, so the results are more informative for this particular subset of patients.
Data from a 2-center registry also support the cardiovascular benefits of combined anticoagulation agents. 18 The study enrolled 426 patients with AF undergoing coronary stenting and the results suggested that compared with dual antiplatelet therapy, the use of warfarin was associated with a significantly lower rate of mortality (17.8% vs 27.8%, P=0.002) as well as MACE (26.5% vs 38.7%, P=0.001), although the major bleeding rate did not statistically significantly differ (14.98% vs 9.0%, P=0.19). However, that study was conducted in European countries, and the majority of subjects Antithrombotic Regimens for AF With DES were white. A previous study suggested that in Asian populations the administration of warfarin was more effective as compared with white populations in the setting of stroke prevention. 19 Consistent with that finding, our data demonstrated a significantly reduced MACCE rate in relation to triple antithrombotic therapy in Asians. Cox regression analysis indicated non-administration of warfarin and a baseline CHADS2 score ≥2 were independent predictors of overall MACCE. Hence, our study results emphasized the superior cardiovascular protective effect of triple therapy over dual antiplatelet therapy, particularly in AF patients whose CHADS2 score is ≥2.
In terms of comparing warfarin plus dual versus single antiplatelet regimen, the largest data set available so far is the GRACE registry. 20 It showed s similar incidence of death and MI at 6 months between the 2 regimens, whereas an approximately 5-fold increased rate of stroke was also noted in favor of the triple antithrombotic regimen (0.7% vs 3.4%, P=0.02). In our study, however, the incidence of stroke was comparably low in patients taking warfarin and either dual or single antiplatelet therapy (0.7% vs 0.8%), while the MACCE rate was similar in both groups, which could be partially explained by the high proportion of clopidogrel (109/125, 87.2%) adoption in the WS group in our study as compared with the GRACE registry, because previous studies have suggested that clopidogrel is more effective than aspirin in preventing stent thrombosis and in reducing death or MI after coronary Stenting. 4,21-23 This finding suggests that in patients whose bleeding risk outweighs the stroke risk, warfarin and single antiplatelet therapy with clopidogrel might be a reasonable treatment option.
Another bewildering problem is the use of DES for AF patients, which has been well documented as reducing restenosis and improving quality of life, 1,24-27 thus becoming the predominant choice for coronary intervention. However, DES are also potentially associated with delayed neointimal coverage 28, 29 and increased risk of late stent thrombosis, 24,26,30,31 requiring prolonged dual antiplatelet therapy for up to 1 year. However, in patients with concomitant oral anticoagulation, prolonged dual antiplatelet therapy may increase the bleeding risk. 32 Therefore, some studies have supported the use of bare mental stents in such patients 33, 34 and that the use of DES should be limited to situations such as long lesions, small vessels, diabetes etc where a significant benefit is expected as compared with bare mental stents. 3 To date there has not been a randomized study comparing the overall safety and efficacy of DES in these situations, so the results from our study could provide valuable information. Unfortunately, because of the inadequate number of patients, the incidence of stent thrombosis and target vessel revascularization was low and did not attain statistical significance among the different regimens. Furthermore, it was a nonrandomized, single-center study, so the baseline characteristics in each group were not well matched. Although we adjusted the baseline characteristics by Cox regression analysis, there might be potential variables that cannot be adjusted.
Even with the aforementioned limitations, our study demonstrated the cardiovascular benefit of triple therapy by reducing MACCE episodes. It is suggested that long-term triple antithrombotic therapy is an effective option for AF patients whose risk of stroke overwhelms the risk of bleeding, if a relatively low target INR value is set and carefully monitored. Additionally, it is imperative that further prospective randomized studies are conducted to further define the best therapeutic strategy for patients with AF undergoing coronary stenting.
